Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CAR-T Meeting 2022 | Evaluating new CAR constructs for chronic hepatitis B and HBV-associated HCC in the clinic

Ulrike Protzer • 8 Feb 2022
CAR-T Meeting 2022
General CAR-T

Ulrike Protzer, MD, Technical University of Munich, Munich, Germany, shares her excitement towards their chimeric antigen receptor (CAR) constructs being investigated as a novel clinical approach to treat chronic hepatitis B and hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC). This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.

Disclosures

Share holder and board member of SCG Cell Therapy.
Ad hoc scientific advisor for AbbVie, Arbutus, Gilead, GSK, Johnson & Johnson, Roche, Sanofi, Sobi, and Vaccitech.

More from Ulrike Protzer

1:33
CAR-T therapy, a novel promising treatment option for chronic hepatitis B and HBV-associated HCC
Ulrike Protzer • 8 Feb 2022
1:12
Rationale for using CAR-Ts to treat chronic hepatitis B
Ulrike Protzer • 8 Feb 2022
2:00
Using T-cell engager antibodies to treat chronic viral hepatitis B and HBV-associated HCC
Ulrike Protzer • 8 Feb 2022

Related Videos

4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals